A Prospective Proteomic-Based Study for Identifying Potential Biomarkers for the Diagnosis of Cholangiocarcinoma
Tóm tắt
Cholangiocarcinoma (CCA) is becoming a common fatal hepatic tumor. Early detection of CCA is hampered by the absence of a sufficiently accurate and noninvasive diagnostic test. Proteomic analysis would be a powerful tool to identify potential biomarkers of this cancer. This study aims to identify new protein markers that are specific for CCA using proteomic approaches and to evaluate the performance of S100 calcium-binding protein A9 (S100A9) and chaperonin-containing TCR1, subunit 3 (CCTγ) as diagnostic markers for screening test of CCA. Two-dimensional differential gel electrophoresis (2-D DIGE) coupled with matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry were used to analyze and screen biomarker candidates in the proteomes of five human CCA samples and five healthy control samples. Subsequently, two potential biomarkers, S100A9 and CCTγ, were chosen for validation and analysis by immunohistochemical methods using CCA tissue microarrays. Twenty protein spots were significantly elevated and five protein spots were downregulated in all patients (p < 0.05). The positive rate was significantly higher in patients with CCA (48 ± 35 %) compared with the normal liver control group (5 ± 10 %, p < 0.001), the hepatocellular carcinoma group (15 ± 20 %, p < 0.001), and the cirrhosis group (12 ± 16 %, p < 0.001). A greater proportion of patients with CCA were positive for CCTγ (72 ± 18 %) compared with the normal liver control group (43 ± 22 %, p < 0.001), the hepatocellular carcinoma group (45 ± 20 %, p < 0.001), and the cirrhosis group (39 ± 25 %, p < 0.001). Combined comparative proteomic analysis using 2-D DIGE and MALDI-TOF is an effective method for identifying differentially expressed proteins in CCA tissues. The expression of S100A9 and CCTγ showed promise as novel diagnostic markers for CCA.
Tài liệu tham khảo
Shaib YH, El-Serag HB, Davila JA, Morgan R, McGlynn KA. Risk factors of intrahepatic cholangiocarcinoma in the United States: a case–control study. Gastroenterology 2005; 128: 620–626
Khan SA, Davidson BR, Goldin R, Pereira SP, Rosenberg WM, Taylor-Robinson SD, Thillainayagam AV, Thomas HC, Thursz MR, Wasan H; British Society of Gastroenterology. Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. Gut 2002; 51 Suppl 6: VI1–VI9
Yoon JH, Gores GJ. Diagnosis, staging, and treatment of cholangiocarcinoma. Curr Treat Options Gastroenterol 2003; 6: 105–112
Gores GJ. Early detection and treatment of cholangiocarcinoma. Liver Transplant 2000; 6: S30 –S34
Van Beers BE. Diagnosis of cholangiocarcinoma. HPB (Oxford) 2008; 10(2): 87–93
Patel AH, Harnois DM, Klee GG, LaRusso NF, Gores GJ. The utility of CA 19–9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis. Am J Gastroenterol 2000; 95: 204–207
Leelawat K, Narong S, Wannaprasert J, Ratanashu-ek T. Prospective study of MMP7 serum levels in the diagnosis of cholangiocarcinoma. World J Gastroenterol 2010; 16(37): 4697–4703
Zhang KJ, Zhang BY, Zhang KP, Tang LM, Liu SS, Zhu DM, Zhang DL. Clinicopathologic significance of slug expression in human intrahepatic cholangiocarcinoma. World J Gastroenterol 2010; 16(20): 2554–2557.
Leelawat K, Sakchinabut S, Narong S, Wannaprasert J. Detection of serum MMP-7 and MMP-9 in cholangiocarcinoma patients: evaluation of diagnostic accuracy. BMC Gastroenterol 2009; 9: 30
Koopmann J, Thuluvath PJ, Zahurak ML, Kristiansen TZ, Pandey A, Schulick R, Argani P, Hidalgo M, Iacobelli S, Goggins M, Maitra A. Mac-2-binding protein is a diagnostic marker for biliary tract carcinoma. Cancer 2004; 101(7): 1609–1615.
He YD. Genomic approach to biomarker identification and its recent applications. Cancer Biomark 2006; 2: 103–133
Wittmann-Liebold B, Graack HR, Pohl T. Two dimensional gel electrophoresis as tool for proteomics studies in combination with protein identification by mass spectrometry. Proteomics 2006; 6: 4688–4703
Ma Y, Peng J, Huang L, Liu W, Zhang P, Qin H. Searching for serum tumor markers for colorectal cancer using a 2-D DIGE approach. Electrophoresis 2009; 30(15): 2591–2599
Robert T, Joanne Sh, Brian M, Rachel R, Steve R, Janice Y, Francois P, Edward H, Lan C, Matthew Davison. Validation and development of fluorescence two-dimensional differential gel electrophoresis proteomics technology. PROTEOMICS 2001; 3: 377–396
Manley S, Mucci NR, De Marzo AM, Rubin MA. Relational database structure to manage high-density tissue microarray data and images for pathology studies focusing on clinical outcome: the prostate Specialized Program of Research Excellence model. Am J Pathol 2001; 1599(3): 837–843
Gebhardt C, Németh J, Angel P, Hess J. S100A8 and S100A9 in inflammation and cancer. Biochem Pharmacol 2006; 72(11): 1622–1631
Lai CC, You JF, Yeh CY, Chen JS, Tang R, Wang JY, Chin CC. Low preoperative serum albumin in colon cancer: a risk factor for poor outcome. Int J Colorectal Dis 2011; 26(4): 473–481.
Coghlin C, Carpenter B, Dundas SR, Lawrie LC, Telfer C, Murray GI. Characterization and over-expression of chaperonin t-complex proteins in colorectal cancer. J Pathol 2006; 210(3): 351–357
Hermani A, Hess J, De Servi B, Medunjanin S, Grobholz R, Trojan L, Angel P, Mayer D. Calcium-binding proteins S100A8 and S100A9 as novel diagnostic markers in human prostate cancer. Clin Cancer Res 2005; 11: 5146–5152
Ichikawa M, Williams R, Wang L, Vogl T, Srikrishna G. S100A8/A9 activate key genes and signaling pathways in colon tumor progression. Mol Cancer Res. 2011; 9(2): 133–148
McKiernan E, McDermott EW, Evoy D, Crown J, Duffy MJ. The role of S100 genes in breast cancer progression. Tumour Biol 2011; 32(3): 441–450
Su YJ, Xu F, Yu JP, Yue DS, Ren XB, Wang CL. Up-regulation of the expression of S100A8 and S100A9 in lung adenocarcinoma and its correlation with inflammation and other clinical features. Chinese Medical Journal 2010; 123(16): 2215–2220
Jang L, He L, Fountoulakis M. Comparison of protein precipitation methods for sample preparation prior to proteomic analysis. J Chromatogr A 2004; 1023: 317–320
Park MR, Wang EH, Jin DC, Cha JH, Lee KH, Yang CW, Kang CS, Choi YJ. Establishment of a 2-D human urinary proteomic map in IgA nephropathy. Proteomics 2006; 6: 1066–1076
Hamada S, Satoh K, Hirota M, Kanno A, Ishida K, Umino J, Ito H, Kikuta K, Kume K, Masamune A, Katayose Y, Unno M, Shimosegawa T. Calcium-binding protein S100P is a novel diagnostic marker of cholangiocarcinoma. Cancer Sci 2011; 102(1): 150–156
Veenstra TD, Conrads TP, Hood BL, Avellino AM, Ellenbogen RG, Morrison RS. Biomarkers: mining the biofluid proteome. Mol Cell Proteomics 2005; 4: 409–418
Zhou M, Conrads TP, Veenstra TD. Proteomics approaches to biomarker detection. Brief Funct Genomic Proteomic 2005; 4: 69–75
López JL. Two-dimensional electrophoresis in proteome expression analysis. J Chromatogr B Analyt Technol Biomed Life Sci 2007; 849:190–202
Taylor RC, Coorssen JR. Proteome resolution by two-dimensional gel electrophoresis varies with the commercial source of IPG strips. J Proteome Res 2006; 5: 2919–2927